Beijing Youfeng

Beijing Youfeng Biomedical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule and peptide drugs. The company primarily focuses on metabolic diseases, oncology, and autoimmune disorders. Its lead candidate, YF-H-201511, is a dual GLP-1 and GIP receptor agonist currently in Phase 2 clinical trials for the treatment of type 2 diabetes and obesity. Additionally, Beijing Youfeng is advancing a pipeline of oncology candidates, including the FGFR inhibitor YF-001 and the HER2-targeted therapy YF-101, as well as the TYK2 inhibitor YF-H-202001 for autoimmune conditions. The company leverages its internal R&D platform to create differentiated therapies aimed at addressing significant unmet medical needs in the global market.